Compounders Research Compare

Mangoceuticals, Inc.(MGRX)

Medical - Healthcare Information Services · Dallas, TX

$0.41-0.01 (-1.63%)

Delayed quote: Oct 6, 2026, 11:25 AM EDT

About Mangoceuticals, Inc.

Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men. These offerings are primarily delivered through a telemedicine platform. The company's product line includes treatments for erectile dysfunction, marketed under the 'Mango' brand. Consumers can purchase these items directly from its official online portal, mangorx.com. Established in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as an affiliate of Cohen Enterprises, Inc.

Dallas, TX

3 employees

www.mangoceuticals.com

Healthcare / Medical - Healthcare Information Services

Sector: Healthcare
Industry: Medical - Healthcare Information Services
CEO: Jacob D. Cohen

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T15:27:46.267Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:27:46.267Z.

Quote observation: 2026-10-06T15:25:25.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 6,977,003
Total debt · period ending 2026-06-30: 324,151
Cash · period ending 2026-06-30: 228,688
TTM free cash flow · period ending 2026-06-30: -3,890,874

FMP input reference: b762030de9532cd090a02a2f6ca20f5433f7bd8b112c678bdb57b8df4aeea120

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

MGRX EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

MGRX Competitors' EV/FCF Ratio

Mangoceuticals, Inc.

Current

Market Cap

$6.98M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NeuroSense Therapeutics Ltd.

Market Cap

$7.02M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Co-Diagnostics, Inc.

Market Cap

$7.13M

EV/FCF Ratio

N/A

TTM Avg

1.99x

3Y Avg

10.75x

5Y Avg

10.75x

Curanex Pharmaceuticals Inc Common Stock

Market Cap

$7.24M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KALA BIO, Inc.

Market Cap

$7.28M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aclarion, Inc.

Market Cap

$6.66M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

InMed Pharmaceuticals Inc.

Market Cap

$7.31M

EV/FCF Ratio

N/A

TTM Avg

41004.37x

3Y Avg

41004.37x

5Y Avg

41004.37x

Enveric Biosciences, Inc.

Market Cap

$6.62M

EV/FCF Ratio

N/A

TTM Avg

2102.49x

3Y Avg

2468.48x

5Y Avg

5853.17x

Longeveron Inc.

Market Cap

$7.43M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Bolt Biotherapeutics, Inc.

Market Cap

$6.49M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Mangoceuticals, Inc. (MGRX)	$6.98M	N/A	N/A	N/A	N/A
NeuroSense Therapeutics Ltd. (NRSN)vs ›	$7.02M	N/A	N/A	N/A	N/A
Co-Diagnostics, Inc. (CODX)vs ›	$7.13M	N/A	1.99x	10.75x	10.75x
Curanex Pharmaceuticals Inc Common Stock (CURX)vs ›	$7.24M	N/A	N/A	N/A	N/A
KALA BIO, Inc. (KALA)vs ›	$7.28M	N/A	N/A	N/A	N/A
Aclarion, Inc. (ACON)vs ›	$6.66M	N/A	N/A	N/A	N/A
InMed Pharmaceuticals Inc. (INM)vs ›	$7.31M	N/A	41004.37x	41004.37x	41004.37x
Enveric Biosciences, Inc. (ENVB)vs ›	$6.62M	N/A	2102.49x	2468.48x	5853.17x
Longeveron Inc. (LGVN)vs ›	$7.43M	N/A	N/A	N/A	N/A
Bolt Biotherapeutics, Inc. (BOLT)vs ›	$6.49M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics